Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2674 - Multicenter Phase I Trial of Trastuzumab Emtansine (T-DM1) in Combination with Non-Pegylated Liposomal Doxorubicin (NPLD) in HER2[+] Metastatic Breast Cancer (MBC). THELMA Study

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Breast Cancer

Presenters

Elena López-Miranda

Citation

Annals of Oncology (2019) 30 (suppl_5): v104-v142. 10.1093/annonc/mdz242

Authors

E. López-Miranda1, S. Di Cosimo2, E. Brain3, M. Ravnik4, S. Escrivá-de-Romaní5, M. Vidal6, J. Gligorov7, S. Borstnar8, L. Calabuig9, M. Sampayo10, J.M. Pérez-García11, F. Riva10, A. Malfettone10, A. Llombart Cussac12, T. Suter13, J. Cortés14

Author affiliations

  • 1 Medical Oncology, Medica Scientia Innovation Research (MedSIR), Ridgewood, New Jersey, USA & Barcelona, Spain; Hospital Universitario Ramón y Cajal, 28034 - Madrid/ES
  • 2 Applied Research And Technological Development, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT
  • 3 Medical Oncology, Hôpital René Huguenin - Institut Curie, 92210 - St. Cloud/FR
  • 4 Medical Oncology, University Medical Centre Maribor, 2000 - Maribor/SI
  • 5 Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 6 Medical Oncology, Hospital Clinic, 08036 - Barcelona/ES
  • 7 Medical Oncology, APHP, CancerEst, Tenon University Hospital, 75020 - Paris/FR
  • 8 Medical Oncology, Institute of Oncology Ljubljana, 1000 - Ljubljana/SI
  • 9 Clinical Operations, Medica Scientia Innovation Research (MedSIR), Ridgewood, New Jersey, USA, 08007 - & Barcelona/ES
  • 10 Project Development Department, Medica Scientia Innovation Research (MedSIR), Ridgewood, New Jersey, USA, 08007 - & Barcelona/ES
  • 11 Medical Oncology, IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), Ridgewood, New Jersey, USA, 08007 - & Barcelona/ES
  • 12 Medical Oncology, Medica Scientia Innovation Research (MedSIR), Ridgewood, New Jersey, USA & Barcelona, Spain; Hospital Arnau de Vilanova, 46015 - Valencia/ES
  • 13 Department Of Cardiology, Inselspital - Universitätsspital Bern, 3010 - Bern/CH
  • 14 Medical Oncology, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain; IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), Ridgewood, New Jersey, USA, 08007 - & Barcelona/ES

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2674

Background

EMILIA, TH3RESA, and KAMILLA phase III trials showed that T-DM1 is highly active and safe as single agent in HER2[+] MBC. T-DM1 and NPLD may be safely combined to increase antitumor effect compared to each agent alone. The aim of this trial is to determine the dose-limiting toxicity (DLT) and maximum tolerate dose (MTD) of T-DM1 plus NPLD in HER2[+] MBC.

Methods

A 3 + 3 dose escalation design was used. Main selection criteria were: (1) Women with HER2[+] MBC ≥ 18 years (yrs); (2) Patients (pts) relapsed or progressed on or after taxanes and trastuzumab-based therapy; (3) No prior treatment with T-DM1 or anthracyclines; (4) Measurable or non-measurable disease with bone lesions. The initial dose was T-DM1 (3.6 mg/kg IV) plus NPLD (45 mg/m2 IV) on Day 1, q3w for up to 6 cycles of NPLD (cohort 1). In the next dose levels, only the NPLD dose was increased to 50 mg/m2 (cohort 2) and 60 mg/m2 (cohort 3). The MTD was the highest dose level at which 0/3 pts or ≤ 1/6 pts experienced DLT during the first 2 cycles. Six additional pts were enrolled at the MTD. T-DM1 treatment was continued as a single agent until disease progression or intolerable toxicity. Secondary objectives included safety, efficacy, and pharmacokinetic (PK) profile.

Results

Fifteen pts were enrolled (cohort 1, n = 3; cohort 2, n = 3; and cohort 3 [NPLD 60 mg/m2 as MTD], n = 9). Median age was 49.5 yrs (range, 31-62), 26.7% received ≥2 prior metastatic treatments, and 80% included trastuzumab plus pertuzumab combination. The only DLT was in the cohort 3 (neutrophil count <0.5x109/L lasted 13 days). The most common ≥G3 adverse events (AEs) were neutropenia (53.3%), AST increase (13.3%), and thrombocytopenia (13.3%). No ≥G3 cardiac AEs occurred. The median duration of treatment and relative dose intensity were 3.7 months and 85%, respectively. The median progression-free survival (mPFS), overall response rate (ORR), and clinical benefit rate (CBR) was 7.2 months, 40%, and 46.7%, respectively. The mPFS, ORR, and CBR in cohort 3 was 7.2 months, 33.3%, and 44.4%, respectively. The analysis of PK profile is ongoing.

Conclusions

T-DM1 plus NDLP is a safe and active combination for pts with previously treated HER2[+] MBC.

Clinical trial identification

NCT02562378. First Posted: September 29, 2015.

Editorial acknowledgement

Legal entity responsible for the study

Medica Scientia Innovation Research (MedSIR); Experior.

Funding

Roche Pharma AG.

Disclosure

E. López-Miranda: Full / Part-time employment: Medica Scientia Innovation Research (MedSIR). S. Di Cosimo: Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy: Pfizer, TEVA, EpiOnpharma, Bayer; Travel / Accommodation / Expenses: Roche, GSK, Celgene; Advisory / Consultancy, Grant reviewer compensation: Swiss Cancer League; Research grant / Funding (institution): EISAI. E. Brain: Research grant / Funding (institution): TEVA (Cephalon), HalioDX (Qiagen/Ipsogen), Amgen; Honoraria (institution), Advisory / Consultancy: AstraZeneca, BMS, Celgene, Clinigen, Hospira, Janssen, Mylan, OBI Pharma, Pfizer, Puma, Roche, Samsung. M. Ravnik: Advisory / Consultancy, Board member: Roche; Advisory / Consultancy, Board member: Pfizer; Advisory / Consultancy, Board member: Eli Lilly; Advisory / Consultancy, Board member: Merck. S. Escrivá-de-Romaní: Advisory / Consultancy: Roche, Pierre Fabre; Speaker Bureau / Expert testimony: Roche, Pierre-Fabre, Kyowa-Kirin, Eisai, Celgene; Travel / Accommodation / Expenses: Roche, Daiichi Sankyo, Pierre Fabre. L. Calabuig: Full / Part-time employment: Medica Scientia Innovation Research (MedSIR). M. Sampayo: Full / Part-time employment: Medica Scientia Innovation Research (MedSIR). J.M. Pérez-García: Advisory / Consultancy: Roche, Lilly; Full / Part-time employment: Medica Scientia Innovation Research (MedSIR). F. Riva: Full / Part-time employment: Medica Scientia Innovation Research (MedSIR). A. Malfettone: Full / Part-time employment: Medica Scientia Innovation Research (MedSIR). A. Llombart Cussac: Honoraria (self), Advisory / Consultancy: Roche, GlaxoSmithKline, Novartis, Celgene, Eisai, AstraZeneca; Research grant / Funding (self): GlaxoSmithKline, Sanofi, Puma Biotechnology; Leadership role, Shareholder / Stockholder / Stock options, Officer / Board of Directors: Medica Scientia Innovation Research (MedSIR). J. Cortés: Advisory / Consultancy: Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex; Honoraria (institution): Roche, Novartis, Celgene, Eisai, Pfizer, Samsung.; Research grant / Funding (institution): Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C, Queen Mary University of London; Advisory / Consultancy, Shareholder / Stockholder / Stock options, Officer / Board of Directors: Medica Scientia Innovation Research (MedSIR). All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.